Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 60 iu/ml;  ; neutral insulin, human, pyr 40 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 60 iu/ml   neutral insulin, human, pyr 40 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx. - treatment of diabetes mellitus.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 50 iu/ml;  ; neutral insulin, human, pyr 50 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 50 iu/ml   neutral insulin, human, pyr 50 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx. - treatment of diabetes mellitus.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 100 iu/ml;   - suspension for injection - 100 iu/ml - active: isophane insulin, human, pyr 100 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 100 iu/ml;   - suspension for injection - 100 iu/ml - active: isophane insulin, human, pyr 100 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa -